Loading
Led the ATTRACTION-2 nivolumab trial and the SPOTLIGHT zolbetuximab trial, two of the defining gastric cancer studies of the decade.
Yoon-Koo Kang is Professor of Medical Oncology at Asan Medical Center in Seoul, specialising in gastric cancer and gastrointestinal stromal tumours. He led ATTRACTION-2, which established the PD-1 antibody nivolumab in late-line gastric cancer in Asia, and SPOTLIGHT, which established zolbetuximab as the first Claudin 18.2-directed therapy, two of the defining gastric cancer studies of the decade. His publications include the ATTRACTION-2 trial of nivolumab in heavily pretreated gastric or gastro-oesophageal junction cancer and the SPOTLIGHT trial of zolbetuximab plus mFOLFOX6 in Claudin 18.2-positive disease. He also led imatinib and other KIT-directed GIST studies.
Shares Asan Medical Center, SPOTLIGHT & GLOW, Zolbetuximab, Claudin 18.2.
Shares SPOTLIGHT & GLOW, Zolbetuximab, Claudin 18.2, Nivolumab.
Shares SPOTLIGHT & GLOW, Zolbetuximab, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
Shares SPOTLIGHT & GLOW, SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer, Zolbetuximab, Claudin 18.2.
Shares SPOTLIGHT & GLOW, Zolbetuximab, Gastric & gastro-oesophageal junction cancer.
Shares Zolbetuximab, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
Shares Zolbetuximab, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
Shares KIT, Imatinib, Sarcomas (soft tissue, bone, GIST).